Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000.
EQNX::TICKER_START (NASDAQ:SILO),(NASDAQ:BXRX),(NASDAQ:HOTH),(NASDAQ:KALA),(NASDAQ:NUWE) EQNX::TICKER_END
/PRNewswire/ -- According to the Centers for Disease Control and Prevention, arthritis affects approximately one in every four Americans, or 58.5 million...
Baudax Bio, Inc. (NASDAQ: BXRX) is engaged as a pharmaceutical company, which is focused on developing innovative products for use
December S&P 500 futures (ESZ22) are trending up +0.23% this morning after three major US benchmark indices snapped a losing streak and closed higher on Thursday as market participants cheered a rise in...
Baudax Bio, Inc. (BXRX) delivered earnings and revenue surprises of -366.04% and 75.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
BXRX, SSB, IBA, CATY and KOF have been added to the Zacks Rank #1 (Strong Buy) List on October 27, 2022.
BXRX, WOLF, GHRS, RKDA and BHR have been added to the Zacks Rank #1 (Strong Buy) List on October 24, 2022.
ANJESO® Net Product Revenue Up 49% Year-Over-Year; Vials Sold to End-Users Up 67% Year-Over-Year Dosing Complete in the First Cohort of the Phase I...
Endo (ENDP) delivered earnings and revenue surprises of 118.75% and 9.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?